Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...

The Shocking Truth" How did Zantac, once the world's most popular drug for acid reflux and heartburn, turn into a toxic ...

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

Reported earnings turn negative Expectedly, the company's reported earnings were affected by the payout for Zantac related settlements. I had last written about GSK earlier this month, following ...

Earlier this month, GSK reached a $2.2 billion settlement to end most of its lawsuits in the US, claiming that its discontinued version of the heartburn drug Zantac caused cancer. It took a £1.8 ...

GSK (LSE: GSK) shares fell 3.4% to 1,401p ... $2.2bn settlement in the US to end most of its lawsuits in relation to Zantac, the heartburn drug that allegedly caused cancer. This issue has long ...

GSK shares fell on Wednesday after the ... s agreement to settle the vast majority of US lawsuits against its Zantac drug without admitting liability. Stripping out the litigation costs, GSK ...